Netherlands-based myTomorrows raises $2.2M to connect patients with development-stage therapies

February 19
7:53 AM 2014

Dutch startup myTomorrows secured $2.2 million more from "friends and family" for its platform that allows patients to have access to drugs that are still in the development stage, TechCrunch reported. The latest proceeds would be added to the $3.8 million earlier invested by myTomorrows President and Co-Founder Ronald Brus and other founders of the company.

The startup seeks to change how individuals suffering from unaddressed medical conditions get access to therapies that are still in the development stage. Drugs categorized as such are still in the clinical trial phase and undergoing a long process to be approved by regulating authorities. myTomorrows specifically focuses on patients who only have a short time left on the hourglass of life because of their condition and for whom therapies that could lengthen or enhance their quality of life are sometimes already available. However, these have not yet been given approval to be sold in the market despite the promising results it exhibited in clinical trials. As of the moment, getting access to these treatments is difficult and even downright impossible. myTomorrows seeks to provide a platform where these patients can link with doctors and drug makers, the report said.

myTomorrows CFO Erdem Yavuz told TechCrunch, "There are great drugs out there that will only be available, if ever, in 3-8 years. Most patients can't wait that long and clinical trials are over selective, or take place in another country, and placebo/control group risks are too high. We allow doctors and biotech companies to help patients with unmet medical needs, given the complicated nature of providing access to development-stage drugs. Patients and their doctors are being empowered to consider newer options."

The platform is now available for patients with conditions like major depressive disorder and cancers of the head and neck, colorectal, renal and prostate. Proceeds of the most recent funding round will be utilized to grow the diseases and geographies it covers, the report said.

© 2022 VCPOST, All rights reserved. Do not reproduce without permission.


Join the Conversation

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics